Compare · BDX vs OFIX
BDX vs OFIX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Orthofix Medical Inc. (OFIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and OFIX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $48.73B, about 116.4x OFIX ($418.7M).
- Over the past year, BDX is down 8.2% and OFIX is down 20.7% - BDX leads by 12.5 points.
- BDX has been more active in the news (11 items in the past 4 weeks vs 6 for OFIX).
- BDX has more recent analyst coverage (25 ratings vs 10 for OFIX).
- Company
- Becton Dickinson and Company
- Orthofix Medical Inc.
- Price
- $176.90-0.08%
- $10.27-3.20%
- Market cap
- $48.73B
- $418.7M
- 1M return
- +17.26%
- -10.46%
- 1Y return
- -8.18%
- -20.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 10
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
Latest BDX
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
- EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,785 worth of shares (75 units at $157.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 20,934 units (SEC Form 4)
- UBS initiated coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest OFIX
- SEC Form S-8 filed by Orthofix Medical Inc.
- SEC Form 10-Q filed by Orthofix Medical Inc.
- Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
- MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
- Orthofix to Participate in Upcoming Investor Conferences
- Orthofix to Report Second Quarter 2026 Financial Results
- Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Pres, Global Ops & Qual Mcpherron Aviva sold $34,425 worth of shares (3,670 units at $9.38), decreasing direct ownership by 5% to 66,330 units (SEC Form 4) to cover withholding tax
- Director Bazaar Alan Lee was granted 14,965 shares, increasing direct ownership by 30% to 65,489 units (SEC Form 4)